News from intercept pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 14, 2013, 06:05 ET

Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results

 Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...

Oct 08, 2013, 21:02 ET

Intercept Announces Pricing of Public Offering of Common Stock By Selling Stockholders

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...

Oct 01, 2013, 16:05 ET

Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)(Intercept), a clinical stage biopharmaceutical company focused on the development and...

Aug 13, 2013, 06:00 ET

Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results

Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...

Aug 05, 2013, 06:00 ET

Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...

Jul 01, 2013, 07:05 ET

Intercept Pharmaceuticals to Present at the JMP Securities Healthcare Conference

 Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...

Jun 24, 2013, 13:30 ET

Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...

Jun 18, 2013, 20:25 ET

Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock

 Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...

Jun 17, 2013, 06:00 ET

Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock

 Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...

May 23, 2013, 08:03 ET

Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference

 Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and...

May 20, 2013, 08:00 ET

Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea

  Intercept Pharmaceuticals, Inc. ("Intercept", NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and...

Sep 04, 2012, 16:01 ET

Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

 Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel...

Aug 09, 2012, 17:24 ET

Intercept Pharmaceuticals Closes $30 Million Series C Financing

 Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel...

Aug 09, 2011, 07:05 ET

Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes

Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier (Servier) today announced that they have entered into a worldwide ex-U.S....

Mar 31, 2011, 13:00 ET

Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind  Phase II clinical trial...

Mar 30, 2011, 06:03 ET

Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease

Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive...

Mar 29, 2011, 07:00 ET

Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals' Obeticholic Acid (INT-747) in NASH

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National...

Jul 28, 2010, 08:00 ET

Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic...

Apr 13, 2010, 08:00 ET

Intercept Pharmaceuticals Presents Positive Phase II Results from Study of INT-747 Therapy in Primary Biliary Cirrhosis at EASL

Intercept Pharmaceuticals, Inc., today announced the presentation of the results from its recently completed Phase II clinical trial of INT-747...

Jan 25, 2010, 08:00 ET

Intercept Pharmaceuticals Raises $25 Million Series B Financing

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic...